ArthroLab has developed very specific expertise in performing studies using different in vivo models to evaluate drug effects on joint tissue/cell metabolism and structural changes.

ArthroLab advises clients on the choice of the optimal models for their specific research goals. The company is particularly renowned for its work with different preclinical models of osteoarthritis and its expert collaboration in early drug development providing critical proof-of-concept data.

ArthroLab also conducts pilot and proof-of-concept studies in preclinical models to determine:

  • Pharmacokinetics
  • Safety
  • Efficacy
  • Disease modifying effect

In addition, ArthroVision, a sister company of ArthroLab, has developed state-of-the-art-technology that, using magnetic resonance imaging (MRI), can quantitatively assess the arthritic changes in experimental models and in humans (see clinical trials). Based on its Cartiscope™ platform, ArthroVision has developed a unique and patented system that provides quantitative evaluation of cartilage degradation and other structural changes associated with the disease progression of osteoarthritis in preclinical and clinical studies.

All rights reserved ArthroLab Inc.